文献速递甲状腺疾病

多聚锌三碘甲状腺原氨酸(PZL)在健康人中延长吸收的1期双盲随机对照研究

Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans.
PubMed 文献 · Thyroid · 2021-12-31

结果显示PZL来源的血清T3峰浓度较LT3低约30%、达峰延迟1小时且平台期延长至6小时,24小时仍超过半峰浓度,而促甲状腺激素降低程度两组相似。PZL具备改善T3药代动力学、提供稳定血清T3水平的特性。

要点

  • PZL来源T3的Cmax较LT3低约30%,Tmax延迟1小时,平台期延长至6小时。
  • PZL组24小时血清T3仍超过Cmax的一半,LT3组24-36小时回落至基线。
  • 两组促甲状腺激素降低程度相似,PZL有望为甲减患者提供稳定T3水平。

核心结论

  • PZL具备实现大幅改善T3药代动力学的必要特性,有望为甲减患者提供稳定的血清T3水平。

研究设计与样本

  • 受试者分三次随机接受安慰剂、50 μg LT3或50 μg PZL胶囊,每次观察48小时,洗脱期2周。

主要发现

  • LT3来源血清T3呈预期 profile,Tmax为2小时,24-36小时回落至基线。
  • PZL来源血清T3的Cmax较LT3低约30%,Tmax延迟1小时,平台期持续长达6小时。
  • PZL组24小时血清T3仍超过Cmax的一半,促甲状腺激素降低程度两组相似。

关键数值与推荐

  • 单次口服50 μg LT3或50 μg PZL后,PZL来源T3的Cmax较LT3低约30%。
  • PZL来源T3的Tmax较LT3延迟1小时,平台期持续长达6小时。
  • PZL组24小时血清T3仍超过Cmax的½,LT3组24-36小时回落至基线。

临床怎么用

  • PZL可能减少口服LT3后的峰值波动,为甲减联合治疗提供更平稳的T3暴露。
  • 需进一步在甲减患者中验证PZL的长期疗效与安全性。

局限性

  • 样本量小、观察期短,未在甲减患者中评估长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: L-triiodothyronine (LT3) has been increasingly used in combination with levothyroxine in the treatment of hypothyroidism. A metal coordinated form of LT3, known as poly-zinc-liothyronine (PZL), avoided in rats the typical triiodothyronine (T3) peak seen after oral administration of LT3. Objectives: To evaluate in healthy volunteers (i) the pharmacokinetics (PK) of PZL-derived T3 after a single dose, (ii) the pharmacodynamics of PZL-derived T3, (iii) incidence of adverse events, and (iv) exploratory analysis of the sleep patterns after LT3, PZL, or placebo (PB) administration. Methods: Twelve healthy volunteers 18-50 years of age were recruited for a Phase 1, double-blind, randomized, single-dose PB-controlled, crossover study to compare PZL against LT3 or PB. Subjects were admitted three separate times to receive a randomly assigned capsule containing PB, 50 μg LT3, or 50 μg PZL, and were observed for 48 hours. A 2-week washout period separated each admission. Results: LT3-derived serum T3 levels exhibited the expected profile, with a Tmax at 2 hours and return to basal levels by 24-36 hours. PZL-derived serum T3 levels exhibited ∼30% lower Cmax that was 1 hour delayed and extended into a plateau that lasted up to 6 hours. This was followed by a lower but much longer plateau; by 24 hours serum T3 levels still exceeded ½ of Cmax. Thyrotropin levels were similarly reduced in both groups. Conclusion: PZL possesses the necessary properties to achieve a much improved T3 PK. PZL is on track to provide hypothyroid patients with stable levels of serum T3.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Dumitrescu AM, Hanlon EC, Arosemena M, et al. Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans. Thyroid. 2021. PMID: 34641706. doi:10.1089/thy.2021.0304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。